From Capital to Commercialization: Q4 2026 Healthcare Investor Briefing

Clinical results and market potential remain important, but regulatory decisions, reimbursement, drug pricing, commercial agreements and technology infrastructure can materially affect the value of a healthcare investment.

Lanton, Lanton & Sosa Law PLLC and Lanton Strategies International B.V. present the Q4 2026 edition of From Capital to Commercialization, examining biotechnology licensing, international pricing, 340B, PBM reform, commercial readiness and AI infrastructure. The briefing is intended for healthcare executives and investors planning for 2027.

Download the full briefing below.

Next
Next

Why European Biotechnology Companies Need a Global Commercial Strategy Before Their Next Funding Round